Anti-Human BCL-2 (124)- Dylight^® 488

Peptide sequence corresponding to residues 41-54 of Human BCL-2

This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2-8°C Wet Ice

Blue Laser (493 nm)

Clone 124 activity is directed against human BCL-2

BCL-2 is a mitochondrial membrane protein, also found in the nuclear envelope and to a lesser degree in the cell membrane, that is detected in lymphocytes, T cells, B cells, primary lymphoid follicles, the mantle zone of secondary follicles, non-lymphoid hematopoietic precursors such as myeloid cells, exocrine gland duct cells, uterine smooth muscle, endometrial glands, thyroid follicles, prostatic glands, breast lobules, fetal epithelial germinative regions, placental trophoblast, endocrine cells and neurons as well as follicular non-Hodgkin’s lymphomas and a variety of other B cell lymphomas and epithelial neoplasms.

BCL-2 is a member of a protein family that regulates apoptosis, with some members inducing (proapoptotic) and others inhibiting (antiapoptotic) apoptosis ¹. BCL-2 acts as an antiapoptotic protein that prevents apoptosis and promotes survival in response to many cell stresses and cytotoxic chemicals ² via the mitochondria-mediated intrinsic apoptosis pathway ¹. BCL-2 is also an important oncogene whose overexpression is common in hematological malignancies such as follicular lymphoma, chronic lymphocytic leukemia, mantle cell leukemia and Waldenström's macroglobulinemia ¹ as well as breast cancer ³. As such, BCL-2 is a target for inhibition in cancer immunotherapy. Additionally, BCL-2 is involved in cardiac hypertrophy and has been suggested as a potential therapeutic target for clinical management ⁴.

Clone 124 was generated by immunizing mice with a synthetic peptide corresponding to amino acids 41 to 54 (GAAPAPGIFSSQPG) of BCL-2 conjugated to thyroglobulin ⁵. Sera were screened on cryostat sections of human tonsil and on a follicular lymphoma with a known 14;18 translocation. Cell fusion and hybridoma lines were produced by conventional technology. 124 recognizes BCL-2 by Western blotting under both reducing and non-reducing conditions.

BAD, BAK proteins

1. Xu Y, Ye H. Exp Hematol Oncol. 11(1):31. 2022.
2. Papadimitriou CS, Costopoulos JS, Christoforidou BP, et al. Eur J Cancer. 33(8):1275-1280. 1997.
3. Merino D, Lok SW, Visvader JE, et al. Oncogene. 35(15):1877-1887. 2016.
4. Meng X, Cui J, He G. Biomed Res Int. 2021:6615502. 2021.
5. Pezzella F, Tse AG, Cordell JL, et al. Am J Pathol. 137(2):225-232. 1990.
6. Monaghan P, Robertson D, Amos TA, et al. J Histochem Cytochem. 40(12):1819-1825. 1992.
7. Lu QL, Hanby AM, Nasser Hajibagheri MA, et al. J Cell Sci. 107 (Pt 2):363-371. 1994.
8. Willingham MC, Bhalla K. J Histochem Cytochem. 42(4):441-450. 1994.
9. Schandl CA, Li S, Re GG, et al. J Histochem Cytochem. 47(2):151-158. 1999.